AstraZeneca Says Combination of Tremelimumab and Imfinzi Antibodies Boosted Liver Cancer Survival
October 15 2021 - 2:49AM
Dow Jones News
By Jaime Llinares Taboada
AstraZeneca PLC said Friday that trials to study the combination
of the tremelimumab monoclonal antibody and Imfinzi demonstrated
overall survival benefit for patients with liver cancer.
Ghassan Abou-Alfa, the principal investigator in the trial, said
the combination of these antibodies boosts the patient's immune
system against liver cancer, aiming to maximize long-term survival
with minimal side effects.
This Phase 3 trial involved 1,324 patients in 16 countries and
compared the tremelimumab-Imfinzi therapy against sorafenib, a
standard-of-care multi-kinase inhibitor.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com;
@JaimeLlinaresT
(END) Dow Jones Newswires
October 15, 2021 02:34 ET (06:34 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Sep 2023 to Sep 2024